Read our insights and commentary about pharmaceutical industry news and healthcare innovation globally. Subscribe to our monthly newsletter to keep up to date with our thought leadership, news, and updates.
Showing 5 of 57 posts
July 14, 2020 | Blogs
CBPartners’ in collaboration with Eric Bernath, explores the current USA access landscape, processes and pitfalls for companion digital therapeutics (DTx), as well as how the space is likely to evolve in the future, and lays out some best practices as suggested by USA payers to maximize chances of reimbursement.
July 6, 2020 | Blogs
Basic science has been redeployed to establish a new understanding of Alzheimer's Disease, focusing on novel biomarkers and cutting-edge therapeutic approaches to slow or reverse disease progression, where the amyloid beta theory has otherwise failed
June 2, 2020 | Blogs
The 2019 NRDL update offers manufacturers key learnings and insights for future NRDL negotiations, particularly with respect to the negotiation tactics used in different disease areas. CBPartners' blog post examines how these learnings can help shape future NRDL negotiations.
April 29, 2020 | Blogs
Cumulative costs from patient enrollment scenarios due to COVID-19 will likely generate a significant financial drain on biopharma R&D expenditures. CBPartners' blog post investigates this impact and explores mitigation strategies.
April 14, 2020 | Blogs
Disruption in healthcare systems across Europe is rife due to the COVID-19 pandemic, with increasingly strained budgets, and shifting healthcare priorities.